Navigation Links
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007,AACR Annual Meeting

7 is currently in clinical studies in the United States. Tapestry plans to initiate multiple Phase II trials for TPI 287 in 2007.

About Tapestry Pharmaceuticals, Inc.

Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer. For more information about Tapestry and its technologies, visit Tapestry's web site at www.tapestrypharma.com.

Forward-Looking Statements

Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward-looking statements include the statements that the Company will initiate Phase II intravenous studies of TPI 287 into the clinic in 2007. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of Phase II protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tapestry Pharmaceuticals Present Data TPI the AACR Annual Meeting
(Date:5/15/2008)...Phase II Data Presented at ASCO Showed Acceptable ...ce of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N...emotherapeutic agent eribulin mesylate (E7389) dem...ion of women with locally advanced or metastatic,b...er Phase II clinical,trial. The study also suggest...
(Date:5/15/2008)...ood pressure reductions demonstrated in Blacks, Hi...etes and Obese Individuals, PARSIPPANY, N.J., May...d today that data presented at the American Societ...c Meeting (ASH 2008) in New,Orleans demonstrated t...pine and olmesartan medoxomil) safely and effectiv...
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
(Date:5/15/2008)...nsiderable Opportunity Remains for an Antiplatelet... Bleeding than the Combination of Plavix/Iscover ...ision Resources, WALTHAM, Mass., May 15 /PRNewswi...ing research and advisory firms for pharmaceutical...Eli Lilly,s Effient offers,improvement in patient ...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3American Society for Microbiology 108th General Meeting 2807 1American Society for Microbiology 108th General Meeting 2807 2Claimsnet Announces Agreement With Aetna for Electronic Claims and Remittance Processing 16244 1Claimsnet Announces Agreement With Aetna for Electronic Claims and Remittance Processing 16244 2New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 1New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 2New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 3New Study Shows the Use of MEDIHONEY 28TM 29 Wound 26 Burn Dressing is Associated With Reduction in Wound Size 16241 4Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 1709 1Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 1709 2Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 1709 3
...r 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:A... 18, 2007 issue of the Journal of Neuroscience a s...and National Jewish,Medical and Research Center de...ble catalytic antioxidant, AEOL 11207, demonstrate...s disease ("PD").,The study also showed that the c...
...ss of Hypertension,Treatment Valsartan in Preventi...YO, April 26, 2007 /Xinhua-PRNewswire/ -- The clin...scale clinical trial,headed by the Jikei Universit...nternationally renowned medical journal The,Lancet...s one of,the largest cardiovascular intervention t...
Other Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 2First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 4
(Date:5/16/2008)...re-USNewswire/ -- This release is,being sent in a ... with the,National Cancer Institute, part of the N... American Society of Clinical,Oncology meeting in ...ctice,in about 25 percent of patients with colon c... way colorectal cancers will be staged., * This n...
(Date:5/16/2008)...ers, WASHINGTON, May 16 /PRNewswire-USNewswire/ -...echnicians in the Greater Portland, Oregon and,Van...ever contract as,Teamsters., "The Teamsters are p...ong contract that gives them job protection and a ...President Jim Hoffa., The workers, both full-time...
(Date:5/16/2008)...icenter Phase III clinical trial has found that th...) significantly delays cancer progression in patie...d worsened on other treatments. The study was led...emorial Sloan-Kettering Cancer Center (MSKCC), who... meeting of the American Society for Clinical Onco...
(Date:5/16/2008)... care medicine is in a precipitous decline, David ...ge of Physicians (ACP), today joined with leading...ue a call for comprehensive reforms to attract, re...ary care physicians. , During a panel discussio...., Dr. Dale and other panelists spoke about the ch...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
...nd that Invitro Fertilization (IVF) resulted in an...ing to the statistics it is found// that the compl...omen who have IFV. Placenta praevia is the common ...ncy. In this the placenta covers part or the entir...
...ospital bed mourning in agony and pain, as a nurse...rom her body//. Her condition seems to be life th...y frame (a classical sign of malnutrition) was see...doctors treating the girl in the western state of ...
...p of commonly used cholesterol-lowering drugs, use...iomyopathy) due to an anti-arrhythmic effect. Sc...nischemic Cardiomyopathy Treatment Evaluation (def...n cardiac deaths with cardiomyopathy due to a surv...
...ple who have suffered from hardships early in thei...ew study reports// that they in reality become mor...ullible adults; this was the finding of a new stud...scientists found that the people who suffered from...
Other Medicine News:Health News:India's Economic Boom Pack To Waste Children Life 2
...Tosoh, innovators of automated random access immun...atured system which builds on the proven reliabili...nced automation, optimum sensitivity, rapid result...Test Menu: Thyroid: TSH TT3 T4 FT3 FT4 T-U...
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory.
...itros ECi brings true automation and continuous ra...ng. Highly sensitive assays for thyroid, anemia, c...bone metabolism testing are currently available, w...he Vitros ECi can simultaneously process 60 access...
The Vitros 250 is a flexible system that can meet requirements in multiple environments small hospitals, backup in large hospitals, clinics and satellite locations. The Vitros 250 also features on-b
Medicine Products: